<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRPO</journal-id><journal-title-group><journal-title>Asian Case Reports in Oncology</journal-title></journal-title-group><issn pub-type="epub">2169-8821</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRPO.2016.53004</article-id><article-id pub-id-type="publisher-id">ACRPO-18150</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRPO20160300000_67182399.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  人附睾蛋白4临床应用研究进展
  Advances of Human Epididymis Protein 4 in Clinical Application
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>雅菲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>托</surname><given-names>娅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>丽娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>内蒙古医科大学附属医院检验科，内蒙古 呼和浩特</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>antuoya@163.com(托娅)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>07</month><year>2016</year></pub-date><volume>05</volume><issue>03</issue><fpage>39</fpage><lpage>44</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   人附睾蛋白4 (human epididymis 4, HE4)是近年来新发现的肿瘤标志物，血清HE4水平作为卵巢癌诊断、疗效评估及预后判断的新指标已经逐渐应用于临床。现有研究显示HE4在肺癌患者血清和恶性胸腔积液患者胸水中呈现较高水平表达，提示其在肺癌诊断、预后评估方面的良好作用。本文就HE4在卵巢癌及肺癌的临床应用作一综述。 Human epididymis protein 4 (HE4) as a novel tumor marker is found in recent years. Serum HE4 level as a new indicator for the diagnosis, therapeutic evaluation and prognosis of ovarian cancer has been applied to the clinical gradually. The existing research shows serum HE4 of patients with lung cancer and HE4 in pleural effusion of patients with malignant pleural effusion presented higher levels of expression, suggesting a good role in the diagnosis and the prognosis evaluation of lung cancer. This article reviews the research of HE4 in clinical application of ovarian cancer and lung cancer.
    
  
 
</p></abstract><kwd-group><kwd>HE4，卵巢癌，肺癌，恶性胸腔积液, HE4</kwd><kwd> Ovarian Cancer</kwd><kwd> Lung Cancer</kwd><kwd> Malignant Pleural Effusion</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>人附睾蛋白4临床应用研究进展<sup> </sup></title><p>王雅菲，托娅<sup>*</sup>，王丽娟</p><p>内蒙古医科大学附属医院检验科，内蒙古 呼和浩特</p><disp-formula id="hanspub.18150-formula39"><graphic xlink:href="http://html.hanspub.org/file/1-2530045x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年7月8日；录用日期：2016年7月26日；发布日期：2016年7月29日</p><disp-formula id="hanspub.18150-formula40"><graphic xlink:href="http://html.hanspub.org/file/1-2530045x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>人附睾蛋白4 (human epididymis 4, HE4)是近年来新发现的肿瘤标志物，血清HE4水平作为卵巢癌诊断、疗效评估及预后判断的新指标已经逐渐应用于临床。现有研究显示HE4在肺癌患者血清和恶性胸腔积液患者胸水中呈现较高水平表达，提示其在肺癌诊断、预后评估方面的良好作用。本文就HE4在卵巢癌及肺癌的临床应用作一综述。</p><p>关键词 :HE4，卵巢癌，肺癌，恶性胸腔积液</p><disp-formula id="hanspub.18150-formula41"><graphic xlink:href="http://html.hanspub.org/file/1-2530045x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>卵巢癌(ovarian cancer)发病率在女性生殖系统肿瘤居第三位，但死亡率居首位。由于发病早期临床症状不明显，大多数患者就诊时已处于癌症晚期阶段，预后不良，所以提高卵巢癌早期检出率是改善患者预后的关键。传统用于卵巢癌筛查的主要方法是妇科超声结合血清糖类蛋白125 (CA125)，但CA125假阳性率较高，临床应用存在一定的局限性。因此亟待找到更可靠的、可以提高卵巢癌早期检出率的肿瘤标志物。近年来HE4作为新型肿瘤标志物被广泛研究，大量研究证实对于早期卵巢癌HE4敏感性高于CA125，被誉为近几十年来第一个能有效的提高卵巢癌早期检出率的肿瘤标志物 [<xref ref-type="bibr" rid="hanspub.18150-ref1">1</xref>] 。同时，HE4在肺癌、恶性胸腔积液患者诊断、鉴别诊断及预后方面良好作用的相关研究，也将为肺癌的临床诊断及预后评估提供新的血清学指标。HE4自发现以来受到各方的密切关注，随着对其研究的与日俱增，HE4在肿瘤发病、病情进展及预后中所起作用得到进一步阐述，这将为肿瘤的生物诊断开辟新的方法。</p></sec><sec id="s4"><title>2. HE4的生物学特性及组织表达</title><p>1991年由Kirchhoff等 [<xref ref-type="bibr" rid="hanspub.18150-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.18150-ref3">3</xref>] 在人类附睾远端上皮细胞中发现位于人类染色体20q12-13.1上的、包含4个内含子和5个外显子的HE4基因。作为乳清酸蛋白(whey acidic proteins, WAP)家族成员之一，HE4分子结构中包含特征性WAP结构域(八个半胱氨酸残基构成的4-二硫化物核心)，因此又被称作是WFDC2基因。HE4是一种分子量较小的、酸性的、富含半胱氨酸的、显示分泌蛋白特性的多肽，属于蛋白酶抑制剂家族中的一种。</p><p>有研究 [<xref ref-type="bibr" rid="hanspub.18150-ref4">4</xref>] 通过对比含有WAP结构域的HE4、弹力素和分泌性白细胞蛋白酶抑制因子，发现三者通过不同的免疫机制均参与了肺部免疫防御，显示了WAP基因家族在组织免疫系统中的重要作用。对于HE4在肿瘤形成中的作用，可通过直接调控HE4组织表达探究其在肿瘤发生、发展等方面的作用机制，Gao等人 [<xref ref-type="bibr" rid="hanspub.18150-ref5">5</xref>] 发现HE4的表达可诱发细胞凋亡的产生，一方面表明其在调节细胞增殖方面的关键性作用，另一方面显示其在ES-2、SKOV-3和T29细胞系体外生长中的抑制作用。同时，研究者将HE4基因转入癌细胞后，发现其能起到抑制细胞转移和活体内移植瘤形成的作用。此外还可通过WAP结构域基因家簇编码的具有高度同源性物质间接体现HE4参与肿瘤形成的作用，Clauss等 [<xref ref-type="bibr" rid="hanspub.18150-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.18150-ref7">7</xref>] 发现卵巢癌中与HE4位于同一基因簇的弹力素高表达，且与患者5年生存率负相关，研究发现可能与其激活了参与炎症相关肿瘤形成的核转录因子——kappa B (NF-κB)信号转导通路有关。</p><p>HE4可以在人体正常组织表达，并非肿瘤特异性表达蛋白。Galgano等人 [<xref ref-type="bibr" rid="hanspub.18150-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.18150-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.18150-ref8">8</xref>] 研究发现，在正常组织中，HE4呈现较高水平表达于唾液腺和呼吸道的上皮细胞中，而卵巢表面上皮HE4阴性表达；在肿瘤组织中，以卵巢浆液性癌阳性表达最高，其次较高水平阳性表达于肺腺癌、乳腺癌、胰腺癌、移行细胞癌，较低水平表达于胃癌、肝癌、结肠癌、前列腺癌。此项研究充分说明了HE4对于卵巢癌与肺癌诊断方面的良好作用。研究证实血清HE4浓度会受到年龄与吸烟状况的影响，其表达与这两者呈正相关性；另外肾功能不全也可使血清HE4浓度显著升高 [<xref ref-type="bibr" rid="hanspub.18150-ref9">9</xref>] 。</p></sec><sec id="s5"><title>3. HE4与卵巢癌</title><p>美国FDA 2008年批准血清酶联免疫吸附试验(ELISA)检测HE4作为诊断卵巢癌的血清学指标 [<xref ref-type="bibr" rid="hanspub.18150-ref10">10</xref>] - [<xref ref-type="bibr" rid="hanspub.18150-ref13">13</xref>] 。我国对于HE4认识起步较晚，对卵巢癌与HE4相关的研究近年来逐渐增加，现就国内近几年卵巢癌与HE4的研究进行总结如下。</p><p>国内研究 [<xref ref-type="bibr" rid="hanspub.18150-ref14">14</xref>] 取健康女性45人、卵巢癌患者28人、卵巢良性疾患者41人，分别用ELISA和电化学发光法检测血清浓度。卵巢癌诊断时，单独检测CA125敏感度为71.5%，特异度为83.5%；单独检测HE4的敏感度为53.6%，特异度为95.2%；HE4联合CA125检测的敏感度为91.6%，特异度为83.6%。HE4检测对卵巢癌诊断有极其关键的作用，与CA125联合检测可使卵巢恶性肿瘤的检出率提高。刘倩等 [<xref ref-type="bibr" rid="hanspub.18150-ref15">15</xref>] 研究发现血清HE4在老年卵巢癌患者表达特异性高，可用于监测老年患者卵巢癌病情变化、疗效及预后的评估。石华等 [<xref ref-type="bibr" rid="hanspub.18150-ref16">16</xref>] 通过研究证实血清HE4水平与卵巢癌病理类型密切相关，HE4是诊断卵巢癌良好的生物学指标之一。另有学者 [<xref ref-type="bibr" rid="hanspub.18150-ref17">17</xref>] 通过ELISA法对21例卵巢癌患者手术及化疗前后血清HE4和CA125水平进行检测。研究显示，术后行常规化疗的卵巢癌患者血清HE4和CA125浓度可基本恢复至正常水平。卵巢癌患者血清HE4与CA125在治疗过程中具有密切相关性(相关系数0.811)。所以，HE4具有评估卵巢癌疗效的潜能。蔡斌等人 [<xref ref-type="bibr" rid="hanspub.18150-ref18">18</xref>] 研究提示年龄为影响人血清HE4表达的重要生理因素之一。女性血清HE4水平应按照60岁以下和60岁以上分别建立参考区间。</p><p>卵巢癌风险评估(Risk of Ovarian Malignancy Algorithm, ROMA)模型是2008年Moore等 [<xref ref-type="bibr" rid="hanspub.18150-ref12">12</xref>] 首次提出，通过计算HE4和CA125的联合指数，用于预测绝经前后女性罹患卵巢癌的可能性。绝经前妇女：PI = −12.0 + 2.38 &#215; LN [HE4] + 0.0626 &#215; LN [CA125]；绝经后妇女：PI = −8.09 + 1.04 &#215; LN [HE4] + 0.732 &#215; LN [CA125]；预测罹患卵巢癌的可能性：ROMA(预测可能性%) = exp(PI)/[1 + exp(PI)] &#215; 100。刘静等 [<xref ref-type="bibr" rid="hanspub.18150-ref19">19</xref>] 通过检索国内外已发表的12篇关于ROMA指数在卵巢癌诊断中临床价值的相关文献，应用循证医学的方法，随机效应模型综合分析效应量，对ROMA指数进行Meta分析，得出ROMA指数在卵巢癌的诊断中的敏感性为89%，特异性为79%，阳性预测值67%，阴性预测值91%，进一步证实了ROMA指数对于卵巢癌的诊断有较高的价值。多位学者 [<xref ref-type="bibr" rid="hanspub.18150-ref20">20</xref>] - [<xref ref-type="bibr" rid="hanspub.18150-ref22">22</xref>] 回顾性分析卵巢癌患者与健康女性的血清水平，计算ROMA指数综合评价卵巢癌的风险性，其结果均证明ROMA指数在卵巢癌的诊断与鉴别诊断方面的灵敏度和特异度比单一检测HE4或CA125要高。目前亚太地区已有多个ROMA多中心实验研究基地，基于中国人群的ROMA多中心研究也已开展，2013年5月西安检验会发布的数据显示，ROMA对存在盆腔肿块的妇女进行危险分层，其敏感性为86%，阴性预测值可达93% [<xref ref-type="bibr" rid="hanspub.18150-ref23">23</xref>] 。</p></sec><sec id="s6"><title>4. HE4与肺癌</title><p>肺癌为人类健康的主要杀手之一，其发病率和死亡率近年来逐年递增 [<xref ref-type="bibr" rid="hanspub.18150-ref24">24</xref>] 。70%的肺癌患者确诊时已呈局部晚期或伴远处转移 [<xref ref-type="bibr" rid="hanspub.18150-ref25">25</xref>] ，但如果早期(肺癌Ia期)发现，其5年生存率可达80% [<xref ref-type="bibr" rid="hanspub.18150-ref26">26</xref>] 。</p><p>Bingle [<xref ref-type="bibr" rid="hanspub.18150-ref4">4</xref>] 发现WFDC2表达于大部分肺癌，局部表达于小细胞肺癌和大细胞肺癌，在肺鳞癌表达却是少数，表明肺癌发生与HE4组织表达存在一定相关性。Yamashita等 [<xref ref-type="bibr" rid="hanspub.18150-ref27">27</xref>] 用免疫组化法确定HE4的表达，临床病理因素和生存率比较结果显示，免疫组化HE4表达与临床病理因素无明确相关性，但腺癌亚型与HE4表达呈显著相关。免疫组化HE4阳性组(44.6%)五年生存率与阴性对照组存在明显差异(82.3%, P = 0.001)，HE4阳性组五年总生存率是60.1%，相比之下，HE4阴性组为90.8% (P = 0.001)。除此之外，淋巴结状态也具有重要参考价值。Iwahori K等 [<xref ref-type="bibr" rid="hanspub.18150-ref28">28</xref>] 用ELISA法对49例肺癌患者和18例卵巢癌患者血清HE4水平进行测定，当临界值设为262.4 pmol/L时，敏感度为89.8%，特异性为100%，血清HE4 ROC曲线下面积(area under the ROC curve, AUC)为0.988，肺癌患者和健康对照组存在显著差异。血清HE4浓度在非小细胞肺癌、小细胞肺癌和卵巢癌患者较健康对照组均显著增高。另外该研究还评估了24例化疗后肺癌患者的血清HE4水平与总体生存率之间的关系，表明化疗后血清HE4的高水平表达(7.5 ng/mL)与治疗后总体生存率密切相关。Tokuishi K等 [<xref ref-type="bibr" rid="hanspub.18150-ref29">29</xref>] 发现HE4-V3与肺癌患者预后密切相关，HE4-V3高表达组5年无病生存期与低表达组相比，预后良好，差异具有显著性(P = 0.002)，HE4-V3高表达组5年总生存率较低表达组显著增高(P = 0.008)。这些数据显示：HE4-V3的高水平表达与肺腺癌的良好预后有关。</p><p>我国学者也做了肺癌与HE4方面研究。肖然等 [<xref ref-type="bibr" rid="hanspub.18150-ref30">30</xref>] 通过ELISA方法检测肺癌患者血清HE4、SCC、CEA、CYFRA21-1、NSE浓度，发现HE4参与的联合检测的诊断阳性率可提升到89.72%。肺腺癌CEA和CYFRA21-1联合检测阳性率为68.46%，而HE4参与的联合检测阳性率则明显提升(82.31%)。肺癌的病理类型及TNM分期对患者HE4血清浓度影响较小 [<xref ref-type="bibr" rid="hanspub.18150-ref31">31</xref>] 。薛霞等 [<xref ref-type="bibr" rid="hanspub.18150-ref32">32</xref>] 证实血清HE4浓度可作为判断肺癌患者预后的独立指标。综上所述，随着更多大样本研究的与日俱增，HE4有望成为肺癌早期诊断、鉴别诊断及预后评估较为理想的新型肿瘤志物。</p></sec><sec id="s7"><title>5. HE4与胸腔积液</title><p>胸腔积液由胸腔内部肿瘤直接侵犯或胸外肿瘤转移至胸膜而致，恶性胸腔积液最常见的病变为肺部肿瘤。Elsammak等 [<xref ref-type="bibr" rid="hanspub.18150-ref33">33</xref>] 将88例胸腔积液患者分为3组，分别为漏出性胸腔积液患者22例，非恶性渗出性胸腔积液患者32例，恶性胸腔积液患者34例，采用免疫法测定血清HE4浓度，结果显示：恶性胸腔积液患者血清HE4水平和胸腔积液HE4水平较漏出性或非恶性渗出性胸腔积液患者显著增高。当胸腔积液临界值为1675 pmol/L，HE4预测恶性胸腔积液的敏感性为85.3%，特异性为90.7%。表明HE4具有作为诊断恶性胸腔积液生物标志物的潜在效能。Hegmans等 [<xref ref-type="bibr" rid="hanspub.18150-ref34">34</xref>] 对胸腔积液蛋白质谱进行研究显示与可溶性间皮素相关蛋白(soluble mesothelin-related proteins, SMRP)相比，HE4在诊断恶性胸膜间皮瘤方面并没有发挥更大作用。目前HE4与良恶性胸腔积液鉴别诊断的相关研究还相对甚少，有待我们进行更进一步的研究考证，从而明确其在胸水性质鉴别应用中的价值。</p></sec><sec id="s8"><title>6. 小结</title><p>本文通过综述不同的研究结果表明，血清HE4浓度与肺癌临床分期、癌组织分化程度及淋巴结转移等关系仍存在争议，相信通过后续更多大样本前瞻性研究，会进一步明确HE4在肺癌诊断及预后评估方面的应用前景。但血清HE4测定受年龄、孕期、吸烟史及肾功能等影响，仍需统一影响因素后行临床试验进一步验证其与相关肿瘤发生发展的关系，从而使HE4在肿瘤诊断及病情监测中发挥更准确、更关键的作用。</p></sec><sec id="s9"><title>基金项目</title><p>内蒙古自治区自然科学基金(2014MS0854)。</p></sec><sec id="s10"><title>文章引用</title><p>王雅菲,托 娅,王丽娟. 人附睾蛋白4临床应用研究进展 Advances of Human Epididymis Protein 4 in Clinical Application[J]. 亚洲肿瘤科病例研究, 2016, 05(03): 39-44. http://dx.doi.org/10.12677/ACRPO.2016.53004</p></sec><sec id="s11"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.18150-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Barbieri, R.L. (2010) In Women Who Have a Pelvic Mass Have You Tried This New Ovarian Cabiomarker? OBG Management, 22, 8-12.</mixed-citation></ref><ref id="hanspub.18150-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kirchhoff, C., Habben, I., Ivell, R., et al. (1991) A Major Human Epididymis-Specific cDNA Encodes a Protein with Sequence Homology to Extracellular Proteinase Inhibitors. Biology of Reproduction, 45, 350-357.  
&lt;br&gt;http://dx.doi.org/10.1095/biolreprod45.2.350</mixed-citation></ref><ref id="hanspub.18150-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bingle, L., Singleton, V. and Bingle, C.D. (2002) The Putative Ovarian Tumour Marker Gene HE4 (WFDC2), Is Expressed in Normal Tissues and Undergoes Complex Alternative Splicing to Yield Multiple Protein Isoforms. Oncogene, 21, 2768-2773. &lt;br&gt;http://dx.doi.org/10.1038/sj.onc.1205363</mixed-citation></ref><ref id="hanspub.18150-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Bingle, L., Cross, S.S., High, A.S., et al. (2006) WFDC2(HE4): A Protential Role in the Innate Immunity of The Oral Cavity and Respiratory Tract and Development of Adenocarcinomas of the Lung. Respiratory Research, 7, 61.  
&lt;br&gt;http://dx.doi.org/10.1186/1465-9921-7-61</mixed-citation></ref><ref id="hanspub.18150-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Gao, L., Cheng, H.Y., Dong, L., et al. (2011) The Role of HE4 in Ovarian Cancer: Inhibiting Tumour Cell Proliferation and Metastasis. Journal of International Medical Research, 39, 1645-1660.  
&lt;br&gt;http://dx.doi.org/10.1177/147323001103900507</mixed-citation></ref><ref id="hanspub.18150-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Clauss, A., Ng, V., Liu, J., et al. (2010) Over Expression of Elafin in Ovarian Carcinoma Is Driven by Genomic Gains And Activation of the Nuclear Factor Kappa B Pathway And Is Associated with Poor Overall Surviva. Neoplasia, 12, 161-172. &lt;br&gt;http://dx.doi.org/10.1593/neo.91542</mixed-citation></ref><ref id="hanspub.18150-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Lin, Y., Bai, L., Chen, W., et al. (2010) The NF kappaB Activation Pathways, Emerging Molecular Targets for Cancer Prevention and Therapy. Expert Opinion on Therapeutic Targets, 14, 45-55.  
&lt;br&gt;http://dx.doi.org/10.1517/14728220903431069</mixed-citation></ref><ref id="hanspub.18150-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Galgano, M.T., Hampton, G.M., Frierson Jr., H.F. (2006) Comprehensive Analysis of HE4 Expression in Normal and Malignant Human Tissues. Modern Pathology, 19, 847-853. &lt;br&gt;http://dx.doi.org/10.1038/modpathol.3800612</mixed-citation></ref><ref id="hanspub.18150-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Karlsen, N.S., Karlsen, M.A., Hogdall, C.K., et al. (2014) HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review. Cancer Epidemiology, Biomarkers &amp; Prevention, 23, 2285-2295. &lt;br&gt;http://dx.doi.org/10.1158/1055-9965.EPI-14-0447</mixed-citation></ref><ref id="hanspub.18150-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Moore, R.G., Brown, A.K., Miller, M.C., et al. (2008) The Use of Multiple Novel Tumor Biomarkers for the Detection of Ovarian Carcinoma in Patients with Pelvic Mass. Gynecologic Oncology, 108, 402-408.  
&lt;br&gt;http://dx.doi.org/10.1016/j.ygyno.2007.10.017</mixed-citation></ref><ref id="hanspub.18150-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Holcomb, K., Vucetic, Z., Miller, M.C., et al. (2011) Human Epididymis Protein 4 Offers Superior Specificity in the Differentiation of Benign and Malignant Adnexal Masses in Premenopausal Women. American Journal of Obstetrics &amp; Gynecology, 205, 358-366. &lt;br&gt;http://dx.doi.org/10.1016/j.ajog.2011.05.017</mixed-citation></ref><ref id="hanspub.18150-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Karisen, M.A., Sandhu, N., Hogdall, C., et al. (2012) Evaluation of HE4, CA125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) as Diagnostic Tools of Epithelial Ovarian Cancer in Patients with a Pelvic Mass. Gynecologic Oncology, 127, 379-383. &lt;br&gt;http://dx.doi.org/10.1016/j.ygyno.2012.07.106</mixed-citation></ref><ref id="hanspub.18150-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">FDA (2014) US Foodand Drug Administration. http://fda.gov</mixed-citation></ref><ref id="hanspub.18150-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">王瑞红. 人附睾分泌蛋白４和CA125对卵巢癌的联合诊断价值[J]. 国际检验医学杂志, 2014, 35(1): 103-104.</mixed-citation></ref><ref id="hanspub.18150-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">刘倩, 郭健. HE4 和 CA125 监测老年卵巢癌转归的价值[J]. 标记免疫分析与临床, 2011, 18(6): 374-379.</mixed-citation></ref><ref id="hanspub.18150-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">石华, 罗蔚, 李文胜, 等. 血清人附睾上皮分泌蛋白水4平检测在卵巢癌的应用价值[J]. 实用妇产科杂志, 2015, 31(4): 267-269.</mixed-citation></ref><ref id="hanspub.18150-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">程洪艳, 刘亚南, 叶雪, 等. 血清人附睾分泌蛋白4(HE4)和CA125在卵巢癌患者手术及化疗前后的变化[J]. 中国妇产科临床杂志, 2011, 12(3): 212-215.</mixed-citation></ref><ref id="hanspub.18150-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">蔡斌, 刘雪莲, 杨懿霞, 等. 913例健康体检女性血清HE4水平分布的初步观察[J]. 实用妇产科杂志, 2012, 28(12): 1045-1049.</mixed-citation></ref><ref id="hanspub.18150-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">刘静, 曲芃芃. ROMA指数在卵巢癌诊断中临床价值的Meta分析[J]. 实用妇产科杂志, 2015, 31(3): 209-213.</mixed-citation></ref><ref id="hanspub.18150-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">王坤, 玉萍, 郭亚琼. ROMA指数在卵巢恶性肿瘤诊断中的应用价值[J]. 标记免疫分析与临床, 2015, 22(7): 666-668.</mixed-citation></ref><ref id="hanspub.18150-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">高岚, 许泼实, 张福明. 血清HE4、CA-125及ROMA指数在卵巢癌诊断中的价值评价[J]. 医药论坛杂志, 2015, 36(9): 8-9.</mixed-citation></ref><ref id="hanspub.18150-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">邓拥军, 郭秋霞. HE4、CA-125、ROMA联合应用诊断卵巢良性与恶性肿瘤的作用[J]. 湖北中医药大学学报, 2015, 17(1): 102-104.</mixed-citation></ref><ref id="hanspub.18150-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">雅培. 中国人群卵巢癌风险评估进展[R]. 全国检验医师大会, 2013.</mixed-citation></ref><ref id="hanspub.18150-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Jemal, A., Siegel, R. and Xu, J. (2010) Cancer Statistics. CA: A Cancer Journal for Clinicians, 60, 277-300. 
&lt;br&gt;http://dx.doi.org/10.3322/caac.20073</mixed-citation></ref><ref id="hanspub.18150-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Molina, J.R., Yang, P., Cassivi, S.D., et al. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factor, Treatment, and Survivorship. Mayo Clinic Proceedings, 83, 584-594. &lt;br&gt;http://dx.doi.org/10.1016/S0025-6196(11)60735-0</mixed-citation></ref><ref id="hanspub.18150-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Mulshine, J.L. and Sullivan, D.C. (2005) Clinical Practice Lung Cancer Screening. The New England Journal of Medicine, 352, 2714-2720. &lt;br&gt;http://dx.doi.org/10.1056/NEJMcp042630</mixed-citation></ref><ref id="hanspub.18150-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Yamashita, S., Tokuishi, K., Hashimoto, T., et al. (2011) Prognostic Significance of HE4 Expression in Pulmonary Adenocarcinoma. Tumor Biology, 32, 265-271. &lt;br&gt;http://dx.doi.org/10.1007/s13277-010-0118-5</mixed-citation></ref><ref id="hanspub.18150-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Iwahori, K., Suzuki, H., Kishi, Y., et al. (2012) Serum HE4 as a Diagnostic and Prognostic Marker for Lung Cancer. Tumor Biology, 33, 1141-1149. &lt;br&gt;http://dx.doi.org/10.1007/s13277-012-0356-9</mixed-citation></ref><ref id="hanspub.18150-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Tokuishi, K., Yamashita, S., Ohbo, K., et al. (2012) Splice Variant HE4-V3 Expression Is Associated with Favorable Prognosis in Pulmonary Adenocarcinoma. Tumor Biology, 33, 103-109. &lt;br&gt;http://dx.doi.org/10.1007/s13277-011-0252-8</mixed-citation></ref><ref id="hanspub.18150-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">肖然, 胡昊昀, 王瑞, 等. 血清肿瘤标志物 HE4 检测在肺癌诊断中的应用价值探讨[J]. 检验医学, 2014, 29(9): 893-896.</mixed-citation></ref><ref id="hanspub.18150-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">于飞, 王倩, 钟殿胜, 等. 血清人附睾蛋白 4 检测对肺癌的诊断意义[J]. 天津医药, 2014, 42(2): 116-118.</mixed-citation></ref><ref id="hanspub.18150-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">薛霞, 杨凡, 单咏梅, 等. 血清人附睾蛋白4检测在肺癌诊断中的意义[J]. 实用检验医师杂志, 2013, 5(2): 96-98.</mixed-citation></ref><ref id="hanspub.18150-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Elsammak, M.Y., Attia, A., Hassan, H.A., et al. (2012) Evaluation of Pleural Fluid Human Epididymis 4 (HE4) as a Marker of Malignant Pleural Effusion. Tumor Biology, 33, 1701-1707. &lt;br&gt;http://dx.doi.org/10.1007/s13277-012-0427-y</mixed-citation></ref><ref id="hanspub.18150-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Hegmans, J.P., Veltman, J.D., Fung, E.T., et al. (2009) Protein Profiling of Pleural Effusions to Identify Malignant Pleural Mesothelioma Using SELDI-TOF MS. Technology in Cancer Research &amp; Treatment, 8, 323-332. 
&lt;br&gt;http://dx.doi.org/10.1177/153303460900800502</mixed-citation></ref></ref-list></back></article>